Research Progress and Future Directions of CRISPR Gene Editing Technology in β-thalassemia
International Journal of Pharma Medicine and Biological Sciences · 01.01.2026 · 29
DOI: 10.18178/ijpmbs.15.2.29-33 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharma Medicine and Biological Sciences, online erschienen am 01.01.2026. Verfasst von Keqi Zhou.
Abstract (Originalsprache)
β-thalassemia is a hereditary hemolytic illness where the synthesis of hemoglobin gets reduced. It mainly comes about because of mutations in the β-globin gene. In the recent few years, CRISPR gene editing technology has been brought in and used to correct the mutations related to β-thalassemia. This paper gives a full look at how CRISPR gene editing technology has been applied in treating β-thalassemia over the past five years. The mechanisms and the latest clinical progress of CRISPR gene editing technology when it comes to treating this disease are explored in a systematic manner through three ways: mending the HBB mutation sites, aiming at the BCL11A enhancer to get fetal hemoglobin activated, and holding back the expression of α-globulin. On November 16, 2023, the UK Medicines and Healthcare Products Regulatory Agency gave the green light to the therapeutic drug Casgevy, which makes use of CRISPR-Cas9 gene editing technology, for treating transfusion-dependent β-thalassemia patients. This marks the start of a new era in gene therapy. But CRISPR gene editing technology still has risks like off-target effects. The appearance of new technologies such as base editors brings a new angle for treatment.
Zitieren
APA
Zhou, K. (2026). Research Progress and Future Directions of CRISPR Gene Editing Technology in β-thalassemia. International Journal of Pharma Medicine and Biological Sciences, 29. https://doi.org/10.18178/ijpmbs.15.2.29-33
Vancouver
Zhou K. Research Progress and Future Directions of CRISPR Gene Editing Technology in β-thalassemia. International Journal of Pharma Medicine and Biological Sciences. 2026:29. doi:10.18178/ijpmbs.15.2.29-33
BibTeX
@article{Zhou2026,
author = {Zhou, Keqi},
title = {Research Progress and Future Directions of CRISPR Gene Editing Technology in β-thalassemia},
journal = {International Journal of Pharma Medicine and Biological Sciences},
year = {2026},
pages = {29},
doi = {10.18178/ijpmbs.15.2.29-33}
}
EUVIMED